CADL Candel Therapeutics
Price Chart
Executive Summary
Candel Therapeutics announced publication of its pivotal Phase 3 trial results for aglatimagene (CAN-2409) in localized prostate cancer in The Lancet Oncology, showing a 30% improvement in disease-free survival (HR 0.70, p=0.016) and a 38% improvement in prostate cancer-specific DFS (HR 0.62, p=0.0046). The company plans to submit a BLA in Q4 2026, supported by this peer-reviewed validation and extended follow-up data showing a 39% improvement in prostate cancer-specific DFS at a median 58-month follow-up.
Actionable Insight
This peer-reviewed publication in a top-tier journal significantly de-risks the BLA submission planned for Q4 2026. The 30% DFS improvement with favorable safety profile positions aglatimagene as a potential new standard-of-care addition to radiotherapy in intermediate-to-high-risk localized prostate cancer. Monitor for BLA acceptance and any partnership discussions ahead of submission.
Key Facts
- Phase 3 trial met primary endpoint: 30% improvement in DFS (HR 0.70, 95% CI 0.52-0.94, p=0.016)
- 38% improvement in prostate cancer-specific DFS (HR 0.62, 95% CI 0.44-0.87, p=0.0046)
- 80% negative biopsy rate at 2 years in aglatimagene arm vs 63% placebo (p=0.0018)
- Extended follow-up (median 58 months) showed 39% improvement in prostate cancer-specific DFS
- BLA submission planned for Q4 2026
- Published in The Lancet Oncology (impact factor 35.9)
- Trial enrolled 745 patients under FDA Special Protocol Assessment
- Fast Track and Regenerative Medicine Advanced Therapy designations from FDA
Financial Impact
Potential multi-hundred-million to billion-dollar market opportunity in localized prostate cancer; BLA submission in Q4 2026 de-risks regulatory path for a first-in-class immunotherapy
Risk Factors
- BLA submission and FDA review carry inherent regulatory risk; approval not guaranteed
- Competition from other localized prostate cancer therapies (e.g., focal therapy, ADT combinations)
- Commercial adoption depends on physician education and reimbursement; Candel has no commercial infrastructure
- Clinical-stage company with no approved products; capital requirements for launch may require dilution
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305133 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
4d ago
|
Press Release
| $8.42 $8.80 | ▲ +4.51% | ▲ +5.21% | $8.51 (+1.07%) |
|
May 15, 2026
22d ago
|
Press Release
| $7.90 $7.66 | ▼ −3.04% | ▼ −2.39% | $8.51 (+7.72%) |
|
May 14, 2026
23d ago
|
8-K
| $8.91 $8.77 | ▼ −1.57% | ▼ −0.34% | $8.51 (−4.49%) |
|
May 14, 2026
23d ago
|
Press Release
| $8.91 $8.77 | ▼ −1.57% | ▼ −0.34% | $8.51 (−4.49%) |
|
May 4, 2026
4w ago
|
Press Release
| $7.53 $7.67 | ▲ +1.86% | ▲ +1.06% | $8.51 (+13.01%) |
|
Apr 29, 2026
5w ago
|
Press Release
| $6.18 $6.18 | · 0.00% | ▼ −1.02% | $8.51 (+37.70%) |
|
Mar 17, 2026
11w ago
|
Press Release
| $5.17 $5.04 | ▼ −2.51% | ▼ −1.12% | $8.51 (+64.60%) |
|
Mar 12, 2026
12w ago
|
8-K
| $4.98 $4.67 | ▼ −6.22% | ▼ −5.63% | $8.51 (+70.88%) |
|
Mar 12, 2026
12w ago
|
Press Release
| $4.98 $4.67 | ▼ −6.22% | ▼ −5.63% | $8.51 (+70.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access